Document text
Principal Investigator: Menghang Xia
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2022
Award: $600,500
Funding agency: National Center for Advancing Translational Sciences
The Tox21 programs federal partners include the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA) and NIH, with leadership from NCATS and the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS). These agencies work together to advance in vitro toxicological testing. The Tox21 Program is comprised of three NCATS teams: Systems Toxicology, Genomic Toxicology, and Computational Toxicology.
The Systems Toxicology team has identified, developed, optimized, and/or screened more than 10 assays. Highlights range from performing 4 online screenings, including gonadotropin-releasing hormone receptor, Muscarinic Ach receptor M1, Kisspeptin receptor, and 5Hydroxytryptamine receptor 2A assays in both agonist and antagonist modes against the Tox21 10K compound library on the Tox21 robotic system.
The US Tox2Program has utilized a quantitative high throughput screening (qHTS) approach to profile thousands of environmental chemicals using a battery of in vitro cell-based assays. The limitation of these assays, particularly those that measure events associated with DNA damage and repair (i.e., genotoxicity), is the absence of a xenobiotic metabolism capability. To overcome this limitation, we investigated methods to incorporate a metabolic component (e.g., liver microsomes) into existing Tox21 assays. We used a p53 beta-lactamase reporter gene assay (p53-bla) as a model system to incorporate metabolic capability into qHTS assays. We screened the Tox21 10K compound library using a p53-bla assay alone or with rat liver microsomes (RLM) or human liver microsomes (HLM) supplemented with NADPH, to identify compounds that induce p53 signaling after biotransformation. Two hundred seventy-eight compounds were identified as active under any of these three conditions. Of these 278 compounds, 73 gave more potent responses in the p53-bla plus RLM assay, and 2 were more potent in the p53-bla plus HLM assay compared with the responses they generated in the p53-bla assay without microsomes. To confirm the role of metabolism in the differential responses, we retested these 75 compounds in the absence of NADPH or with heat-attenuated microsomes. Forty-four compounds treated with RLM, but none with HLM, became less potent under these conditions, confirming the role of RLM in metabolic activation. Further evidence of biotransformation was obtained by measuring the half-life of the parent compounds in the presence of microsomes. Taken together, our study indicates that this approach can identify compounds that are not be detected by standard screening methods that lack metabolic capability.
Assessing irritation and sensitization potential is a key element in the safety evaluation of topical drugs and other consumer products such as cosmetics. To evaluate the compounds for their irritation and sensitization potential, we tested about 500 topically applied compounds by using monolayer skin cells and three-dimensional culture models including reconstructed human epithelial and full-thickness skin models by measuring tight junctions, cell viability, and cytokine secretions for assessing chemical irritation and sensitization. This study represents the first step in advocating for replacement of current animal tests with bio-engineered skin models. To develop an HTS comparable method of direct peptide reactivity assay (DPRA) that has been used for assessing compound sensitization potential, we modified DPRA assay measuring the amount of free cysteine or lysine peptide from traditionally using a high-performance liquid chromatography platform to a high throughput tandem mass spectrum system, which greatly increases the screening throughput. Recently, we have validated and screened KeratinoSens Nrf2-ARE-Luc assay against the Tox21 10K compound library to identify the compounds with sensitization potential. After primary screening, we identified a group of Nrf2/ARE activators and further evaluated them in a battery of in vitro assays including DPRA, IL-8, and human cell line activation test (hCLAT).
AChE is the primary cholinesterase in the body that metabolizes a key neurotransmitter, acetylcholine. Inhibition of AChE activity can lead to neurotoxicity and known inhibitors include organophosphorus pesticides, chemical warfare agents, drugs, and various phytochemicals. To identify environmental chemicals that inhibit AChE activity using in vitro models, we have used enzyme- and cell-based AChE inhibition assay to screen the Tox21 10K compound library. From the primary screening, over 100 AChE inhibitors have been identified. These compounds were further studied their AChE inhibition in SH-SY5Y and human neuron stem cells (hNSC) in monolayer culture vs spheroid culture. Some AChE inhibitors showed more potency in hNSC spheroid culture compared to monolayer culture, while higher expression levels of CYP3A4 and CYP2D6 were found in spheroids than in monolayer culture, suggesting CYP enzymes were involved in bioactivation. To explore the interactions between AChE and their inhibitors, we used a molecular docking analysis to study the binding mode of these AChE inhibitors and found that all the AChE inhibitors were predicted to bind the active sites of the AChE. Using this approach, we identified a group of known AChE inhibitors and many previously not reported AChE inhibitors including some AChE inhibitors that need metabolic activation. Many of these AChE inhibitors were marketed drugs, withdrawn drugs, or unapproved drug candidates. They compared IC50s of these AChE inhibitors with human plasma concentrations (Cmax) from the literature and calculated the ratios of IC50 over Cmax. A common benchmark indicating physiological relevance is IC50/Cmax < 10. Using these ratio values can prioritize AChE inhibitors for further in-depth study.
Since the outbreak of a global pandemic coronavirus disease-19 (COVID-19), various potential therapeutic agents for COVID-19 are being investigated worldwide mainly through the drug repurposing approach. Many drugs employed as anti-viral may exert unwanted side effects (i.e., toxicity) via unknown mechanisms. To quickly assess these drugs for their potential toxicological effects and mechanisms, we used the Tox21 in vitro assay datasets generated from screening 10,000 compounds consisting of approved drugs and environmental chemicals against multiple cellular targets and pathways. Many these drugs were shown to be active modulators in our nuclear receptor signaling pathway assays. Several signaling pathways including AR, Nrf2/ARE, ER, FXR, ER stress, and targets like HDAC were reported for their role in regulating ACE2 and TMPRSS2 expression, which are the main host cell factors that aid in SARS-CoV-2 pathogenicity. Some of the drugs in our study were shown to be cytotoxic against a wide range of cells and they include chlorpromazine, curcumin, emetine, lopinavir, ritonavir, niclosamide, and nitazoxanide. The cytotoxicity of these compounds might be due to their target promiscuity as shown by their activities in multiple Tox21 in vitro assays. Although in vitro cytotoxicity assays were used to screen chemicals/drugs for their relative toxicities at micro-molar concentrations, these assays can identify a potential hazard due to the multiple uses or high doses of the drugs when administered in humans. These qHTS data are publicly available and can provide valuable information on drug activities and their off-target effects, which can be further investigated for their potential uses in treating COVID-19 infection.
Terms: <2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-10C><3-D><3-Dimensional><3D><ACE2><ACh Receptors><AMCF-I><Acetylcholine><Acetylcholine Receptors><Ache><Active Sites><Acylcholine acylhydrolase><Acylcholineacylhydrolase><Adherent Culture><Advocate><Agonist><Animal Testing><Antioncogene Protein p53><Assay><Attenuated><Benchmarking><Best Practice Analysis><Binding><Bioassay><Biochemical Pathway><Biologic Assays><Biologic Models><Biological><Biological Assay><Biological Models><Biomedical Engineering><Biotransformation><Blood Plasma><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><CP34><CPD6><CV-19><CV19><CXCL8><CYP 2D6><CYP2D><CYP2D6><CYP2D6 gene><CYP2DL1><CYP3><CYP3A><CYP3A4><CYP3A4 gene><CYPIID6><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Survival><Cell Viability><Cells><Cellular Assay><Cellular Tumor Antigen P53><Chemical Warfare Agents><Chemicals><Chlorpromazine><Cholinergic Receptors><Cholinesterases><Cholinoceptive Sites><Cholinoceptors><CoV-2><CoV2><Coenzyme II><Collaborations><Common Rat Strains><Consumption><Cosmetics><Curcumin><Cysteine><Cytochrome P-450 CYP2D6><Cytochrome P450 2D6><Cytochrome P450 3A4><Cytochrome P450 Subfamily IID Polypeptide 6><Cytochrome P450, Subfamily IIIA, Polypeptide 4><Cytochrome P450PCN1><DNA Damage Repair><DNA Repair><Data><Data Set><Dataset><Debrisoquine 4-Hydroxylase><Debrisoquine 4-Monooxygenase><Debrisoquine Hydroxylase><Diferuloylmethane><Disease Outbreaks><Docking><Dose><Drugs><ER stress><Elements><Emetine><Engineered skin><Environmental Protection Agency><Enzyme Gene><Enzymes><Epithelial><Epitheliasin Gene><Evaluation><Event><FAMILY III P450><Follicle Stimulating Hormone-Releasing Hormone Receptors><Food and Drug Administration><G24 protein><GCP1><Genomics><Glucocorticoid-Inducible P450><GnRH Receptors><Goals><Gonadoliberin Receptors><Gonadorelin Receptors><Gonadotropin-Releasing Hormone Receptor><HDAC><HDAC Proteins><HPLC><Half-Cystine><Half-Life><Health><High Performance Liquid Chromatography><High Pressure Liquid Chromatography><High Speed Liquid Chromatography><High Throughput Assay><Histone Deacetylase><Human><Human Cell Line><IL-8><IL8><IL8 gene><Imipramine 2-Hydroxylase><In Vitro><Intermediary Metabolism><Intracellular Communication and Signaling><Investigators><Ipecine><K60><KISS1><KISS1 Metastasis Suppressor><KISS1 gene><Kaletra><KiSS-1><L-Cysteine><L-Lysine><LHRH Receptors><Lead><Leadership><Libraries><Literature><Liver Microsomes><Lopinavir/Ritonavir><Luliberin Receptors><Luteinizing Hormone Releasing-Hormone Receptor><Lysine><Lytotoxicity><M1 receptor><MGC39258><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Medication><Metabolic><Metabolic Activation><Metabolic Biotransformation><Metabolic Networks><Metabolic Processes><Metabolism><Metastin><Methods><Methylcephaeline><Microsomes><Mission><Model System><Modeling><Modern Man><Molecular><Molecular Interaction><Monolayer culture><Muscarinic Agents><Muscarinic M1 Receptor><Muscarinics><NAD phosphate><NAD(H) phosphate><NADH phosphate><NADP><NADPH><NCATS><NIEHS><NIH><National Center for Advancing Translational Sciences><National Institute of Environmental Health Sciences><National Institutes of Health><National Toxicology Program><Nerve Cells><Nerve Transmitter Substances><Nerve Unit><Neural Cell><Neurocyte><Neurons><Neurotransmitters><Nicotinamide-Adenine Dinucleotide Phosphate><Nifedipine Oxidase><Nuclear Receptors><Occluding Junctions><Oncoprotein p53><Outbreaks><P450-2D6><P450-DB1><P450C2D><P450C3><P450DB1><P450PCN1><P53><PRSS10><Parents><Pathogenicity><Pathway interactions><Pb element><Peptides><Pesticides><Pharmaceutic Preparations><Pharmaceutical Preparations><Phosphoprotein P53><Phosphoprotein pp53><Physiologic><Physiological><Phytochemical><Plasma><Plasma Serum><Progenitor Cells><Protein TP53><Rat><Rats Mammals><Rattus><Receptor Protein><Reporter Genes><Reporting><Research Personnel><Researchers><Reticuloendothelial System, Serum, Plasma><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SCYB8><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Sparteine Monooxygenase><Specificity><Steroid-Inducible P450- III><Subfamily IID Cytochrome P450><Subfamily IID-Like 1 Cytochrome P450><System><TMPRSS2><TMPRSS2 gene><TP53><TP53 gene><TRP53><TSG-1><Testing><Therapeutic Agents><Thick><Thickness><Tight Junctions><Time><Topical Drug Administration><Topical application><Toxic effect><Toxicities><Toxicology><Triphosphopyridine Nucleotide><Tumor Protein p53><Tumor Protein p53 Gene><Turmeric Yellow><USFDA><United States Environmental Protection Agency><United States Food and Drug Administration><United States National Institutes of Health><Unscheduled DNA Synthesis><Viral><Work><Wuhan coronavirus><Xenobiotic Metabolism><Zonula Occludens><administer topically><angiotensin converting enzyme 2><angiotensin converting enzyme II><antagonist><apply topically><b-ENAP><base><beta lactam hydrolase><beta-Lactamase><beta-Lactamhydrolase><bio-engineered><bio-engineers><bioengineering><biologic><biological engineering><biological signal transduction><biological systems><cell assay><cell dimension><cellular targeting><chemical warfare substances><choline esterase II><computational toxicology><computer based prediction><consumer product><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><cosmetic product><cytokine><cytotoxic><cytotoxicity><deliver topically><design><designing><drug candidate><drug market><drug repurposing><drug/agent><ecological toxicology><endoplasmic reticulum stress><environmental chemical><environmental toxicology><genotoxicity><hCoV19><hazard><heavy metal Pb><heavy metal lead><high throughput screening><in vitro Assay><in vitro Model><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibitor><irritation><kisspeptin><monolayer><nCoV2><neuron toxicity><neuronal><neuronal toxicity><neurotoxicity><nitazoxanide><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><prediction model><predictive modeling><programs><protein p53><receptor><repurposing agent><repurposing medication><response><robotic system><screening><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><side effect><social role><stem cells><three dimensional><topical administration><topical delivery><topical drug application><topical treatment><topically administered><topically applied><topically delivered><topically treated><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treat topically><β-Lactamase>